Abu-Amer Nabil, Beckerman Pazit
Institute of Nephrology and Hypertension, Sheba Medical Center, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Israel.
Harefuah. 2021 Apr;160(4):210-214.
Treatment of atherosclerotic renal artery stenosis (RAS) is still controversial. Several randomized controlled trials have shown that percutaneous transluminal renal angioplasty with stenting (PTRAS) is not superior to medical treatment, and the procedure is commonly reserved for malignant hypertension, flash pulmonary edema or deterioration of kidney function. The most challenging symptomatic RAS cases are patients with severe stenosis resulting in acute kidney injury (AKI) requiring acute hemodialysis. The risk-benefit ratio in these cases is uncertain. While those patients might benefit the most from revascularization, the success rate after prolonged time on dialysis is unknown. This is a representative case study of a patient with solitary kidney and high grade RAS who presented with anuric AKI indicated for hemodialysis. Twenty-eight days after starting hemodialysis the patient underwent PTRAS as a rescue therapy and 5 days after the procedure urine output resumed, the patient became polyuric and kidney function improved and the patient stopped hemodialysis.
动脉粥样硬化性肾动脉狭窄(RAS)的治疗仍存在争议。多项随机对照试验表明,经皮腔内肾血管成形术加支架置入术(PTRAS)并不优于药物治疗,该手术通常适用于恶性高血压、急性肺水肿或肾功能恶化。最具挑战性的有症状RAS病例是严重狭窄导致急性肾损伤(AKI)需要急性血液透析的患者。这些病例的风险效益比尚不确定。虽然这些患者可能从血运重建中获益最大,但长期透析后的成功率尚不清楚。这是一例有代表性的病例研究,患者为单肾且患有高级别RAS,出现无尿性AKI,需进行血液透析。开始血液透析28天后,患者接受PTRAS作为挽救治疗,术后5天尿量恢复,患者出现多尿,肾功能改善,停止血液透析。